66 results about "Cerebral edema" patented technology

The invention belongs to the technical field of nerve regulation and control engineering, and provides a cerebrospinal fluid rhythm-based Alzheimer's disease electrical stimulation system, which is characterized in that first frequency band range data and second frequency band range data in brain wave signals are coupled to obtain cerebrospinal fluid rhythm data; then, calculating the phase difference between the first frequency band range data and the cerebrospinal fluid rhythm data; finally, the stimulation frequency is dynamically controlled according to the phase difference, and the stimulation current is dynamically controlled according to the brain tissue water volume fraction. The problem that specific metabolism requirements of non-fast eye movement sleep and fast eye movement sleep cycles cannot be matched by adopting single-frequency-band stimulation is solved, dynamic changes of post-traumatic encephaledema and requirements and influences of cerebrospinal fluid rhythm on current control are considered, the real-time adaptive capacity to the dynamic changes of the post-traumatic encephaledema is improved, and the application prospect is wide. And the treatment effect of the Alzheimer's disease is ensured.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention belongs to the technical field of medical treatment, and discloses application of dehydroequol to treatment of neonatal hypoxic ischemic encephalopathy. The dehydroequol is used for treating the neonatal hypoxic-ischemic encephalopathy, and it is proved that the dehydroequol can reduce the area of cerebral infarction induced by hypoxia and ischemia, relieve encephaledema and inhibit oxidative stress and copper death, and has a treatment effect on neonatal hypoxic-ischemic brain injury. Dehydroequol is a medicine for treating hypoxic ischemic encephalopathy of newborns and has a development prospect.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention relates to the technical field of medical biology, in particular to application of coriaria lactone or a medicinal derivative thereof in preparation of AD (Alzheimer's disease) treatment drugs. The coriaria lactone shows unique structural activity and treatment specificity, the epoxyhexane ring structure of the coriaria lactone is a key active group and is enriched in an A beta sedimentary area through synaptic gaps, the ion disturbance range is limited in a lesion microenvironment (the radius is lt and 50 microns), and wide tissue damage caused by physical electrical stimulation is avoided. The micromolecule characteristic (LogP = 1.8) of the coriaria lactone endows the coriaria lactone with the ability of spontaneously penetrating the blood brain barrier, the onset time is shortened to the hour level from several months, and meanwhile, the risk of encephaledema is avoided. Therefore, the compound can be used for preparing the medicine for treating the Alzheimer's disease, meanwhile, a proper dosage is screened, and a foundation is laid for research on preparation of the medicine for treating the AD.

The invention discloses a cerebral infarction risk early warning method and system based on an image feature change trend, and relates to the technical field of cerebral infarction early warning. The cerebral infarction risk early warning method comprises the steps of feature extraction, wherein image data and modal data are processed through a feature analysis method, and image features, image feature change data, modal data features, modal data feature change data and regions where the features are located are obtained; the image data provides visual information of a brain structure and a focus, the modal data supplements key features such as hemodynamics, brain tissue electrical activity and electrical impedance from different physiological dimensions, the TCD data can monitor blood flow velocity and vascular resistance in real time, and the BI data is sensitive to change of pathological states such as encephaledema. The EEG data reflects the subtle change of the electrical activity of neurons, and the image feature change trend is corrected through feature extraction and analysis and combination of multi-source heterogeneous data, so that the accuracy of cerebral infarction risk early warning is ensured.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The application discloses a kind of bioengineered apoptotic bodies based on apoptotic body membrane protein and liposome and preparation method and application thereof.The bioengineered apoptotic bodies are formed by the chimerization of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5.The bioengineered apoptotic bodies simulating the natural apoptosis process of mesenchymal stem cells can promote the polarization of microglial cells to M2 type, release anti-inflammatory factors and neurotrophic factors, promote the proliferation of neurons, improve the antioxidant capacity of cells, improve the nervous motor function, relieve brain edema, and thus effectively treat traumatic brain injury.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The invention belongs to the technical field of biological medicines, and relates to a high-throughput screening method based on cell membrane nano-vesicles and application of a screened drug afloqualone in resisting encephaledema. Through a screening model, it is surprisingly found that the drug afloqualone AFQ on the market has the remarkable effect of inhibiting water inflow and encephaledema. The glibenclamide pharmaceutical composition shows a curative effect superior to that of glibenclamide in an animal model, can effectively reduce the volume of cerebral infarction, reduce the death rate in an acute stage and improve neurological impairment, and is known to have good clinical safety and good clinical application prospects. The invention provides a brand-new treatment strategy with a great clinical application prospect for solving the problem of lack of effective medicines for post-stroke encephaledema at present.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The application relates to an epilepsy monitoring and electric stimulation system and method, wherein the epilepsy monitoring and electric stimulation system comprises a multi-modal signal acquisition module, an electric stimulation module, a control module and a set of ring-shaped common electrodes distributed on a human head; in the multi-modal signal acquisition module, an electric impedance acquisition unit obtains impedance characteristics when the common electrodes are in a first acquisition state, and an electroencephalogram acquisition unit obtains electroencephalogram characteristics when the common electrodes are in a second acquisition state; the control module is used for evaluating an epilepsy pre-onset time, a lesion site and a brain edema degree based on the impedance characteristics, combining the two characteristics to evaluate an epilepsy grade, then setting electric stimulation parameters according to the brain edema degree and the epilepsy grade, selecting an electric stimulation electrode pair according to the lesion site, and controlling the electric stimulation module to apply electric stimulation with the parameters to the electrode pair before the epilepsy pre-onset time, and adjusting the parameters according to real-time signals in the stimulation. Through the application, the problems of low positioning accuracy and inability to intervene in time before epilepsy onset in the related art are solved.

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

The application provides a non-invasive multi-modal brain function monitoring method and device, electronic equipment and storage medium, and relates to the technical field of multi-modal electric digital data processing. The method comprises the following steps: acquiring physiological state information of a measured target and electroencephalogram monitoring data, brain oxygen monitoring data and brain edema monitoring data of the measured target within a preset time length; determining electroencephalogram infection artifacts of the measured target according to the physiological state information, and removing the electroencephalogram infection artifacts from the electroencephalogram monitoring data to obtain real electroencephalogram data; correcting the brain oxygen monitoring data according to the physiological state information and the real electroencephalogram data to obtain real brain oxygen data; determining a brain function level of the measured target based on the physiological state information, the real electroencephalogram data, the real brain oxygen data and the brain edema monitoring data, and performing brain injury early warning according to the brain function level. The application can timely and accurately predict the change of the brain function of a child with severe infection through multi-modal monitoring data.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The application provides a cerebral apoplexy postoperative sign monitoring system, which is fused with a nerve motor function evaluation wristband and a head-mounted brain electrical impedance dynamic imaging device, and breaks through the blind area of postoperative monitoring. The wristband device collects upper limb electromyographic signals and joint motion mechanics parameters through a microneedle electrode array and a distributed piezoresistive sensor, drives a neural network to output a standardized motor score based on time-frequency domain features containing electromyography, joint angle, trajectory smoothness and grip force change rate, and is related to a clinical Fugl-Meyer scale; the imaging device adopts a multi-ring electrode array and an improved D-bar algorithm to reconstruct a brain electrical conductivity distribution map, constructs a multi-level decision tree early warning model by extracting impedance change rate Delta Z, spatial gradient entropy SGE and hemisphere asymmetry Asym, and realizes brain edema detection. Through multi-modal data fusion and minute-level response, the system solves the fragmentation problem of postoperative monitoring and provides precise decision support for cerebral apoplexy rehabilitation.

The invention belongs to the technical field of nursing vests, and discloses a multi-mode vital sign intelligent nursing vest which comprises a front vest, and a patch opening is formed in the front face of the front vest. By arranging the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, due to the design of the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, respiration, electrocardio, body temperature and muscular tension of a patient can be monitored in real time, and monitored data are transmitted to the single chip microcomputer; the single-chip microcomputer monitors vital signs and neurological function changes of a patient in real time through an AI algorithm, automatically warns the risk of encephaledema, epileptic seizure or reperfusion injury, and transmits the monitored vital signs and neurological function changes of the patient to the medical system through the data transmission module. Meanwhile, when it is monitored that the vital signs and the neurological functions of the patient are abnormal, an alarm is given out through the alarm to remind medical staff.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

The invention discloses a TREM1 specific antagonistic peptide based on AI de novo design and application thereof, and belongs to the technical field of biological medicine. The novel antagonistic peptide Pep457 is finally obtained by taking an immunoglobulin-like structural domain of TREM1 protein as a target spot, performing de novo design by utilizing an RFdiffusion model and combining molecular docking and binding free energy calculation, and detecting and evaluating the in-vitro inhibitory activity of the novel antagonistic peptide Pep457, and the amino acid sequence of the novel antagonistic peptide Pep457 is shown as SEQ ID NO: 1. In a traumatic brain injury mouse model, the Pep457 can remarkably relieve blood brain barrier damage, relieve encephaledema, inhibit neuroinflammation and neuronal apoptosis and effectively promote movement and cognitive function recovery. The invention provides a novel efficient candidate drug for treating TREM1 related inflammatory diseases, especially traumatic nerve injury, and has an important clinical application prospect.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

The application discloses a calculation method and system for the transmission and scattering process of low-frequency electromagnetic waves in the brain, and relates to the technical field of brain detection. The method simplifies the brain tissue into a homogeneous isotropic spherical model, which significantly reduces the calculation complexity and lays a foundation for efficient solution. Then, an electromagnetic wave propagation and scattering physical model based on Maxwell's equations is constructed to accurately describe the motion law of electromagnetic waves in brain tissue. The physical model is deeply integrated into a deep learning algorithm to efficiently solve the three-dimensional electromagnetic field distribution in the brain. Finally, the propagation path, energy distribution and scattering field characteristics of electromagnetic waves are analyzed to realize the positioning and qualitative diagnosis of brain edema, tumors and other lesions, and provide key support for brain tissue health assessment. The application overcomes the efficiency bottleneck of traditional numerical methods in brain electromagnetic calculation, improves the timeliness and accuracy of brain disease diagnosis, and provides reliable technical support for bedside rapid diagnosis of acute conditions such as stroke.

Provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of acute high-altitude illnesses caused by acute high-altitude hypobaric hypoxia. The acute high-altitude illnesses include, for example, acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). Additionally provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of high-altitude pulmonary hypertension (HAPH) and inflammatory responses caused by acute high-altitude hypobaric hypoxia.

This invention discloses a method and system for predicting the risk of malignant cerebral edema after mechanical thrombectomy in ischemic stroke, aiming to address the pain points of existing prediction tools, such as insufficient accuracy, lack of clinical interpretability, and difficulty in directly supporting decision-making. The core solution involves: stably extracting key predictive variables from multi-source clinical and laboratory data through a multi-algorithm consensus feature selection mechanism (LASSO, Boruta algorithm); employing eight machine learning algorithms to select the best high-performance prediction model, and using repeated cross-validation and grid search for robust optimization; innovatively and deeply integrating the SHAP interpretability framework to achieve global, local, and individualized interpretation of the model predictions; and finally deploying it as an integrated clinical decision support system, outputting a visual report that combines risk probability, risk classification, and decision-making basis. This method significantly improves the early risk identification capability of malignant cerebral edema, and the model exhibits excellent discrimination and calibration.

This disclosure provides medicaments and methods for treating envenomation using small molecule inhibitors of secretory phospholipase A2 (sPLA2). The sPLA2 inhibitor AZD2716 and related compounds can be used as monotherapy. Alternatively, the sPLA2 inhibitor varespladib and / or methyl varespladib can be used in combination with a statin. When a subject has been envenomed (for example, by a snake bite or bee sting), the medicaments can be administered to prevent lethal effects or tissues damage cause by the venom: for example, acute kidney injury, mast cell degranulation, or cerebral edema. The medicaments may be contained in an automatic injection device or an injection pen to deliver an effective dose as soon as possible following envenomation.

The invention relates to an epilepsy monitoring electrical stimulation system and method.The epilepsy monitoring electrical stimulation system comprises a multi-mode signal acquisition module, an electrical stimulation module, a control module and a set of common electrodes annularly distributed on the head of the human body; in the multi-mode signal acquisition module, an electrical impedance acquisition unit obtains impedance characteristics when the common electrode is in a first acquisition state, and an electroencephalogram acquisition unit obtains electroencephalogram characteristics when the common electrode is in a second acquisition state; the control module is used for evaluating the epilepsy pre-onset time, the focus part and the encephaledema degree based on the impedance characteristics, and evaluating the epilepsy grade in combination with double characteristics; determining electrical stimulation parameters according to the encephaledema degree and the epilepsy grade, and selecting an electrical stimulation electrode pair according to the focus part; and before the epilepsy pre-onset time, controlling the electrical stimulation module to apply electrical stimulation conforming to the parameters to the electrode pair, and adjusting the parameters according to real-time signals during stimulation. According to the invention, the problems of low positioning precision and incapability of timely intervention before epileptic seizure in the prior art are solved.

The invention discloses a bioengineering apoptotic body based on apoptotic body membrane protein and lipidosome as well as a preparation method and application of the bioengineering apoptotic body. The bioengineered apoptotic body is formed by chimeric combination of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5. The bioengineered apoptotic body for simulating the natural apoptosis process of the mesenchymal stem cells is constructed, microglial cells can be promoted to be polarized to an M2 type, anti-inflammatory factors and neurotrophic factors are released, neuronal proliferation is promoted, the cell oxidation resistance is improved, the neuromotor function is improved, and encephaledema is relieved, so that traumatic brain injury is effectively treated.